| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10017614 | HBV | ENSG00000259207.10 | protein_coding | ITGB3 | No | No | 3690 | P05106 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ITGB3 |
|---|---|
| DrugBank ID | DB00054 |
| Drug Name | Abciximab |
| Target ID | BE0001155 |
| UniProt ID | P05106 |
| Regulation Type | antagonist |
| PubMed IDs | 11588534; 12165285; 17441904; 11752352; 18510478; 12749745 |
| Citations | Amoroso G, van Boven AJ, van Veldhuisen DJ, Tio RA, Balje-Volkers CP, Petronio AS, van Oeveren W: Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease. J Cardiovasc Pharmacol. 2001 Oct;38(4):633-41.@@Weber AA, Meila D, Jacobs C, Weber S, Kelm M, Strauer BE, Zotz RB, Scharf RE, Schror K: Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors. Thromb Res. 2002 Apr 1;106(1):25-9.@@Hall PR, Malone L, Sillerud LO, Ye C, Hjelle BL, Larson RS: Characterization and NMR solution structure of a novel cyclic pentapeptide inhibitor of pathogenic hantaviruses. Chem Biol Drug Des. 2007 Mar;69(3):180-90.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Mazzaferri EL Jr, Young JJ: Abciximab: a review and update for clinicians. Expert Rev Cardiovasc Ther. 2008 Jun;6(5):609-18. doi: 10.1586/14779072.6.5.609.@@Ibbotson T, McGavin JK, Goa KL: Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63. |
| Groups | Approved |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | Abciximab Action Pathway |
| PharmGKB | PA448006 |
| ChEMBL | CHEMBL1201584 |
